Literature DB >> 7913786

A fully automated apparatus for a light/dark test measuring anxiolytic or anxiogenic effects of drugs in mice.

M Imaizumi1, T Suzuki, H Machida, K Onodera.   

Abstract

We developed a fully automated light/dark apparatus which detects locomotion, rearing and time spent in light and dark zones, and shuttle crossing of mice. This apparatus is controlled by a personal computer and detects these parameters by using infrared beamsensors. We used this apparatus to investigate the effects of the anxiolytics, diazepam (DZP) and pentobarbital (PB); the putative anxiolytic, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT); and the anxiogenics, picrotoxin, methyl-beta-carboline-3-carboxylate (beta-CCM), and ethyl-beta-carboline-3-carboxylate (beta-CCE), on each parameter measured by a light/dark test in mice. DZP (5 mg/kg) and 8-OH-DPAT (0.1 and 0.2 mg/kg) significantly increased the time spent in the light zone. PB (10 mg/kg) also significantly increased the number of shuttle crossings between the dark and light zones. Conversely, picrotoxin (1 and 2 mg/kg) significantly decreased locomotion, rearing and time spent in the light zone. beta-CCM (10 mg/kg) and beta-CCE (5 mg/kg) also significantly decreased rearing and time spent in the light zone. Although the same dose of beta-CCE significantly decreased shuttle crossing and rearing in the dark zone, beta-CCE did not change locomotion in either zone. Our results indicate that this apparatus is useful for the assessment of the anxiolytic and anxiogenic activities of drugs in mice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913786

Source DB:  PubMed          Journal:  Nihon Shinkei Seishin Yakurigaku Zasshi        ISSN: 1340-2544


  6 in total

1.  Effects of acute or chronic administration of novel 3,4-dimethoxyphenylethylamine derivates on anxiety-like behavior.

Authors:  Julia Fedotova; Victoria Barishpolec; Anthony Zulli; Dietrich Büsselberg; Ludovit Gaspar; Peter Kruzliak
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

2.  Antidepressant & anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide: A novel serotonin type 3 receptor antagonist in behavioural animal models.

Authors:  Dilip Kumar Pandey; Thangraj Devadoss; Neha Modak; Radhakrishnan Mahesh
Journal:  Indian J Med Res       Date:  2016-10       Impact factor: 2.375

3.  Effects of subacutely administered saiboku-to, an oriental herbal medicine, on pharmacodynamics and pharmacokinetics of diazepam in rodents.

Authors:  M Yuzurihara; Y Ikarashi; K Ishihara; H Kushida; A Ishige; H Sasaki; Y Maruyama
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Apr-Jun       Impact factor: 2.569

4.  Neurological disorders in a murine model of chronic renal failure.

Authors:  Jean-Marc Chillon; François Brazier; Philippe Bouquet; Ziad A Massy
Journal:  Toxins (Basel)       Date:  2014-01-03       Impact factor: 4.546

5.  Neurological characterization of mice deficient in GSK3α highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase.

Authors:  Hervé Maurin; Benoit Lechat; Ilse Dewachter; Laurence Ris; Justin V Louis; Peter Borghgraef; Herman Devijver; Tomasz Jaworski; Fred Van Leuven
Journal:  Mol Brain       Date:  2013-05-25       Impact factor: 4.041

6.  Anti-anxiety effect of a novel 5-HT₃ receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice.

Authors:  Yeshwant Vijay Kurhe; Mahesh Radhakrishnan; Devadoss Thangaraj; Deepali Gupta
Journal:  Indian J Pharmacol       Date:  2014 Jan-Feb       Impact factor: 1.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.